Open AccessFrequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Author(s) -
Steinberg Benjamin A.,
Shrader Peter,
Pieper Karen,
Thomas Laine,
Allen Larry A.,
Ansell Jack,
Chan Paul S.,
Ezekowitz Michael D.,
Fonarow Gregg C.,
Freeman James V.,
Gersh Bernard J.,
Kowey Peter R.,
Mahaffey Kenneth W.,
Naccarelli Gerald V.,
Reiffel James A.,
Singer Daniel E.,
Peterson Eric D.,
Piccini Jonathan P.
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007633
Subject(s) - medicine , atrial fibrillation , hazard ratio , vitamin k antagonist , confidence interval , dosing , proportional hazards model , stroke (engine) , observational study , cardiology , warfarin , mechanical engineering , engineering
Non-vitamin K antagonist oral anticoagulants (NOACs) are indicated for stroke prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to describe the frequency, appropriateness (according to Food and Drug Administration labeling), and outcomes of patients prescribed reduced doses of NOACs in community practice.